CLL Key Data-Readouts from ASH 2020 CLL Current Tx paradigm/Unmet need commentary CLL treatment paradigm has seen a significant shift from chemoimmunotherapy to targeted therapies such a BTK inhibitors, PI3K inhibitors and the novel time- limited combinations....
How Pembrolizumab Became Oncology’s Closest Thing to a “Silver Bullet” Are genius molecules a product of nature or nurture? OCTOBER 2020 Kevin Baruzzi, Dr. Arun R. Shrivats and Daria Andreeva Among the available cancer treatments, pembrolizumab is an industry...
Five Organizing Principles for New Product Planning Success New product planning fails more often than it succeeds. Prescient’s Global Head of Advisory looks at why this happens and outlines a structured approach to fixing the problem. SEPTEMBER 2020 Dr. Debasish...
Dr. Paul HarneyPresident, North America Virtual workshops have different planning requirements compared to similar events that might take place face to face. Prescient has produced a white paper that details five essential elements for running effective virtual...
Pharma Companies’ Response to the COVID-19 Pandemic How are pharma companies battling the tough conditions imposed by the pandemic? JULY 2020 Dr. Nick Turner, Senior Director In our previous blog post, COVID-19’s Impact on the Pharma Industry, we highlighted the major...
